Belinda Graham, MD
Allergy & Immunology · Smyrna, GANPI 1770786915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,813 of the $94,343 with a category attached, or 60.2%. Regeneron Healthcare Solutions, Inc. accounts for 61.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $35,470 and has fallen 54.0% since, to $16,322 in 2025. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 688 payments — averaging $137.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$58K
- GSK$14K
- AstraZeneca$7K
- Genentech, Inc.$4K
- Sanofi$3K
- Novartis$3K
- plus $6K from 28 others
What the payments were for
- Consulting fees$10,59411%
- Speaking & faculty fees$56,81360%
- Travel & lodging$9,67810%
- Food & beverage$17,10318%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 122 | $58,255 |
| GSK | 98 | $13,866 |
| AstraZeneca | 87 | $6,935 |
| Genentech, Inc. | 6 | $4,220 |
| Sanofi | 97 | $2,768 |
| Novartis | 24 | $2,741 |
| Optinose US, Inc. | 67 | $932 |
| Amgen(2 entities) | 46 | $926 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $718 |
| Blueprint Medicines Corporation | 6 | $393 |
| Covis Pharma GmbH | 15 | $344 |
| Biocryst US Sales Co., LLC | 10 | $344 |
| Pfizer | 12 | $260 |
| Pharming Healthcare, Inc. | 10 | $254 |
| Genentech USA, Inc. | 7 | $233 |
| Grifols USA, LLC | 9 | $181 |
| Sanofi-aventis U.S. LLC | 2 | $154 |
| Kaleo, Inc. | 9 | $147 |
| CSL Behring | 6 | $143 |
| Teva Pharmaceuticals USA, Inc. | 6 | $105 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $86 |
| Alk-abello, Inc | 3 | $51 |
| Phadia US Inc. | 3 | $44 |
| Boehringer Ingelheim | 2 | $37 |
| Abbott | 1 | $30 |
| Galderma Laboratories, L.p. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Greer Laboratories, Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Regeneron | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,343 in reported general payments places this provider in the 90th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 73 | $415,536 |
| Dupixent PenDupilumab | 67 | $266,389 |
| XolairOmalizumab | 32 | $116,294 |
| TezspireTezepelumab-Ekko | 23 | $113,723 |
| XembifyImmune Globulin,gamma(Igg)klhw | 21 | $110,750 |
| Dupixent SyringeDupilumab | 28 | $109,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $71,978 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $25,547 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $13,607 |
| Epinephrine | 58 | $12,288 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,717 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,989 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,340 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $4,700 |
| Azelastine Hcl | 126 | $4,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $718 | $415,53673 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $6,935 | $136,67076 claims |
| Genentech, Inc.Xolair | $4,220 | $116,29432 claims |
| Grifols USA, LLCXembify | $181 | $110,75021 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13,866 | $97,525145 claims |
| Boehringer IngelheimSpiriva Respimat | $37 | $10,71711 claims |
| MerckDulera | $15 | $3,60411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Smyrna
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
- Ronald BeebeGainesville$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.